Nuvation Bio Inc. splits its revenue into 3 lines in its filings. The largest line in Q3 of fiscal 2026, the quarter ended Sep 30, 2026 was Product at $27.5 million, 61% of the total.
USD in millions. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Sep 30, 2026
|
Q3 FY2026
Sep 30, 2026
|
Q2 FY2026
Jun 30, 2026
|
Q1 FY2026
Mar 31, 2026
|
Q4 FY2025
Dec 31, 2025
|
Q3 FY2025
Sep 30, 2025
|
Q2 FY2025
Jun 30, 2025
|
Q1 FY2025
Mar 31, 2025
|
Q4 FY2024
Dec 31, 2024
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
202
|
45
|
32
|
83
|
42
|
13
|
5
|
3
|
6
|
| Product |
85
share 42.1%
|
27
+255.5%
share 61.1%
|
23
+1773.3%
share 73.2%
|
19
share 22.2%
|
16
share 37.5%
|
8
share 58.9%
|
1
share 25.6%
|
—
|
—
|
| License |
117
+557.1%
share 57.9%
|
17
+224.1%
share 38.9%
|
8
+136.3%
share 26.8%
|
65
+1998.5%
share 77.8%
|
26
+42298.4%
share 62.5%
|
5
share 41.1%
|
4
share 74.4%
|
3
share 100.0%
|
-0
share -1.1%
|
| Research And Development Service Revenue |
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
4
share 63.5%
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- NUVB (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1811063
- Former names
- Panacea Acquisition Corp (until Feb 11, 2021)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.